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Rotterdam, the Netherlands; and New York, New YorkOBJECTIVES This study sought to determine the clinical and angiographic variables that would
identify patients with high-risk “vulnerable” coronary plaques.
BACKGROUND In the PROSPECT (Providing Regional Observations to Study Predictors of Events in the
Coronary Tree) study, in patients successfully treated for acute coronary syndrome (ACS), plaque composi-
tion, plaque burden, and minimal luminal area as detected by 3-vessel radiofrequency intravascular ultra-
sound (IVUS) imaging were associated with an increased risk of developing future events from untreated
atherosclerotic lesions (vulnerable plaques). Whether baseline demographic and angiographic ﬁndings
can be used to identify patients most likely to have vulnerable coronary plaques has not been examined.
METHODS On the basis of 3-vessel radiofrequency IVUS imaging, patents in the PROSPECT trial were
classiﬁed in 2 groups according to whether or not one or more untreated high-risk plaques were present,
deﬁned as having$2 high-risk features (a thin-cap ﬁbroatheroma, plaque burden$70%, and/or minimal
luminal area #4 mm2).
RESULTS The high-risk group (those with one or more high-risk lesions) had higher Framingham risk
score (7.5  3.4 vs. 6.9  3.3; p ¼ 0.04), more extensive coronary artery disease, and more nonculprit
lesion–related cardiovascular events during the 3-year follow-up (hazard ratio: 2.63; 95% conﬁdence in-
terval: 1.62 to 3.66; p < 0.0001). However, demographic factors had poor discrimination in detecting
high-risk patients (area under the curve 0.55), and discrimination was only slightly improved when angio-
graphic variables were entered into the model (area under the curve 0.64).
CONCLUSIONS Clinical and angiographic characteristics had poor predictive accuracy in identifying
patients with untreated high-risk plaques related to future adverse events. This ﬁnding highlights the po-
tential value of comprehensive 3-vessel imaging assessment (either invasive or noninvasive) to evaluate
plaque phenotype for more accurate risk stratiﬁcation of patients admitted with ACS. (J Am Coll Cardiol
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1264ntravascular ultrasound (IVUS) with radio-
frequency backscatter analysis provides visualiza-
tion of the entire vessel wall; assessment of the
luminal, outer vessel wall, and plaque dimensions;
and reliable semiautomated detection of plaque
components and quantiﬁcation of their burden
(1,2). This imaging modality is therefore useful in
the research of atherosclerosis (3,4). Several studies
used serial backscatter analysis of IVUS signal ex-
aminations to assess changes in the composition of
the plaque and the effect of pharmaceutical treat-
ment (5–7). In the recently reported PROSPECTSee page 1273(Providing Regional Observations to Study Pre-
dictors of Events in the Coronary Tree) study,
3-vessel IVUS–virtual histology (VH) imaging was
used to evaluate the prognostic implications of the
composition of the plaque and its burden in patientsrome
brane
ound
ea
ry
omaadmitted with acute coronary syndrome
(ACS) (6). Consistent with prior patho-
logical studies, the PROSPECT trial
demonstrated that plaque composition, as
well as burden, were predictors of future
cardiovascular events (6,8).
The 3 characteristics in the PROSPECT
trial that were associated with future ad-
verse lesion-speciﬁc cardiovascular events,
namely plaque burden, minimal luminal
area, and thin-cap ﬁbroatheroma (TCFA)
as deﬁned by IVUS-VH, required 3-vessel
catheter-based interrogation for identiﬁca-
tion, a procedure not without risk (6).Several studies have shown that the composition and
extent of atheroma are associated with cardiovascular
risk factors and that they differ in patients admitted
with different clinical presentations (3,9–12).
Therefore, baseline demographics or a combination
of clinical and angiographic variables may allow
detection of patients who have lesions with plaque
features related to an increased risk for cardiovas-
cular events, possibly allowing a targeted approach
to imaging. The aim of the present analysis was
therefore to identify clinical and angiographic
characteristics related to the high-risk plaques in
the PROSPECT study and to construct a model
that will allow accurate detection of patients with a
vulnerable plaque phenotype.
METHODS
Study population. The design, inclusion and ex-
clusion criteria, and endpoints and deﬁnitions of thePROSPECT study have already been described
in detail (6). The PROSPECT trial included
697 patients admitted for an acute coronary event
(i.e., ST-segment elevation myocardial infarction,
non–ST-segment elevation myocardial infarction,
or unstable angina) who had successful per-
cutaneous coronary intervention in all culprit le-
sions. The studied patients underwent coronary
angiography and 3-vessel grayscale and IVUS-VH
(Volcano Corp., San Diego, California) imaging of
the proximal 6- to 8-cm coronary segments using a
synthetic aperture array, 20 MHz, 3.2-Fr catheter
(Eagle Eye, Volcano Corp.), after intracoronary
nitroglycerin administration.
Data analysis. The acquired angiographic, IVUS,
and IVUS-VH data were transferred to an inde-
pendent core laboratory (Cardiovascular Research
Foundation, New York, New York) and analyzed,
blinded to the baseline and clinical characteristics.
Quantitative coronary angiographic (QCA) analysis
was performed, with the use of the software
Medis CMS (version 7.0, Leiden, the Netherlands)
in the entire length of the coronaries and the side
branches that had a reference diameter >1.5 mm.
All stenoses >30% on coronary angiography were
analyzed, and the following metrics were obtained:
lesion length, reference diameter, minimal lumen
diameter, and diameter stenosis. Lesions related to
the event were characterized as culprit and the rest
as nonculprit lesions.
IVUS and IVUS-VH analysis was conducted
with the use of QCU-CMS (Medis) software for
contouring, pcVH 2.1 (Volcano Corp.) for contour-
ing and data output, and proprietary software
(qVH, Cardiovascular Research Foundation) for
segmental qualitative and quantitative output. The
external elastic membrane (EEM) and the lumen
borders were detected at approximately every
0.5-mm interval (depending on the heart rate and the
R-R interval) and used to determine the EEM area,
lumen area, and plaque area and burden (deﬁned as
100  plaque area/EEM area). Nonculprit IVUS
lesions were deﬁned as >3 consecutive IVUS frames
visualizing segments with a plaque burden $40%.
IVUS-VH allows characterization of 4 different
plaque components that are portrayed in a color-
codedmap, with the red corresponding to the necrotic
core, green to ﬁbrous tissue, light green to ﬁbrofatty,
and white to dense calcium. Based on its composi-
tional traits, each lesion was classiﬁed as TCFA,
thick-cap ﬁbroatheroma, pathological intimal thick-
ening, ﬁbrotic plaque, and ﬁbrocalciﬁc plaque (2).
The IVUS-derived independent lesion charac-
teristics, which were associated with future adverse
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1265cardiac events (i.e., presence of a TCFA, plaque
burden $70%, and minimal lumen area #4 mm2)
were used to classify the study population into
2 groups: the high-risk group included patients who
had at least 1 lesion, with $2 of the 3 high-risk
characteristics, whereas the low-risk group in-
cluded the remaining patients, those without any
high-risk lesions (6,9).
Clinical endpoints. The primary endpoint of the
PROSPECT study was the composite incidence of
major adverse cardiac events (MACE), consisting of
cardiac death or arrest, myocardial infarction, or
rehospitalization for unstable or progressive angina,
as adjudicated by an independent clinical events
committee. MACE were classiﬁed as related to
culprit lesions if they arose from a previously treated
lesion or not related to culprit lesions if they arose
from an untreated lesion. If follow-up angiography
was not performed, the lesion causing the event was
classiﬁed as indeterminate.
Statistical analysis. Continuous variables are pre-
sented as median with 25th and 75th percentiles or
mean  SD, and binary variables are shown as ab-
solute values and percentages. The Mann-Whitney
U test was used for independent 2-sample com-
parisons of continuous variables, and the Fisher
exact test was used to compare binary variables.
Graphical plots were made by the Kaplan-Meier
method. The log-rank statistic was used to compare
prognosis between the 2 groups. Cox regression anal-
ysis was performed to identify independent predictors
of cardiovascular events. The proportionality of haz-
ards assumption was examined by residual plotting.
Binary logistic regression analysis was performed to
identify factors associated with the high-risk group.
Variables with a p value<0.2 were used to construct a
multivariable model. In case of collinearity (r > 0.8
and p < 0.05), the variables that had a higher level of
signiﬁcance were eligible for inclusion in the multi-
variable model. A p value <0.05 (2 tailed) was
considered statistically signiﬁcant. A risk score was
assigned to each independent predictor based on the
odds ratio (OR), and a total risk score was then
calculated for each patient. The discriminatory capa-
bility of the developed score to identify patients that
belonged to the high-risk group was assessed using
the area under the receiver-operating characteristics
curve. Data analysis was performed using SAS version
9.2 (SAS Institute, Cary, North Carolina).
RESULTS
Patient characteristics. From the 697 patients
recruited in the PROSPECT study, 609 patientswere included in the current analysis because 88
patients did not have complete 3-vessel IVUS-VH
examinations. The patients allocated to the high-
risk group were more likely to have a higher Fra-
mingham risk score and increased triglyceride levels.
No other signiﬁcant differences were noted in the
baseline demographics between the 2 groups
(Table 1).
Angiographic ﬁndings. The results of the QCA
analysis are shown in Table 2. A total of 609 lesions
were identiﬁed in the high-risk (n ¼ 200) and 897
in the low-risk (n ¼ 409) groups. The high-risk
group had more extensive coronary artery disease
with a greater number of nonculprit lesions and
diseased coronary arteries and side branches. There
were no differences in the maximum diameter ste-
nosis of the nonculprit lesions or the angiographic
characteristics of these stenoses.
IVUS and IVUS-VH ﬁndings. IVUS identiﬁed 3,014
lesions, of which 1,097 were detected in the
high-risk (n ¼ 200) and 1,917 in the low-risk
(n ¼ 409) groups. The length of the diseased seg-
ments was greater in the high-risk patients who
also had a smaller mean EEM and lumen area;
there were no differences between the 2 groups in
the mean plaque area (Table 3). As expected by
the criteria used to create the groups, high-risk,
compared with low-risk, patients had a higher
incidence of lesions with a minimum lumen area
(MLA) #4 mm2 (31.8% vs. 11.4%; p < 0.0001)
and plaque burden $70% (18.4% vs. 3.3%;
p < 0.0001). In contrast to QCA, IVUS revealed
signiﬁcant differences between the 2 groups in the
luminal dimensions at the site of the nonculprit
lesions, with the high-risk group having a smaller
MLA. IVUS-VH analysis showed that the lesions
in high-risk patients had a greater proportion of
necrotic core and dense calcium, whereas lesions in
low-risk patients had signiﬁcantly more ﬁbrofatty
tissue. Accordingly, TCFAs were more frequently
present in the high-risk group, whereas pathological
intimal thickening was more prevalent in the low-
risk group.
Clinical outcomes. Online Table 1 demonstrates the
cumulative 3-year event rate (overall, culprit related,
nonculprit related, and undetermined) in the overall
study population and the high-risk and low-risk
groups. The high-risk group had an increased rate
of nonculprit lesion MACE, driven mainly by a
higher rehospitalization rate due to unstable or
progressive angina symptoms. High-risk status was
a predictor of nonculprit lesion–related MACE by
univariable analysis (hazard ratio: 2.63; 95% conﬁ-
dence interval [CI]: 1.62 to 3.66; p < 0.0001)
Table 1. Baseline Characteristics of the Study Population and the High-Risk and Low-Risk Groups
Study Population
(N [ 609)
High-Risk Group
(n [ 200)
Low-Risk Group
(n [ 409) p Value
Age, yrs 58.2 (50.7–67.2) 57.7 (50.4–67.1) 58.5 (50.9–67.2) 0.74
Male 466 (77) 154 (77) 312 (76) 0.84
Height, cm 173 (166–178) 172 (168–178) 173 (165–178) 0.33
Weight, kg 83 (73–95) 83 (73–94) 82.5 (73–96) 0.99
Body mass index, kg/m2 27.9 (25.1–31.2) 28.2 (25.3–31.0) 27.9 (25.1–31.4) 0.52
Systolic blood pressure, mm Hg 130 (118–145) 135 (119–150) 130 (117–142) 0.056
Diastolic blood pressure, mm Hg 75 (68–84) 75 (68–84) 75 (68–83) 0.88
Clinical presentation
ST-segment elevation MI 179 (29) 62 (31) 117 (29) 0.54
Non–ST-segment elevation MI 407 (67) 131 (66) 276 (68) 0.63
Unstable angina 23 (4) 7 (4) 16 (4) 0.80
History of CAD 80 (13) 30 (16) 50 (12) 0.27
History of coronary intervention 65 (11) 22 (11) 43 (11) 0.84
Congestive heart failure 12 (2) 3 (2) 9 (2) 0.76
Family history of CAD 244 (46) 82 (49) 162 (44) 0.23
Hypertension 285 (47) 102 (52) 183 (45) 0.12
Hypercholesterolemia 252 (45) 88 (47) 164 (44) 0.56
Diabetes mellitus 107 (17) 43 (22) 64 (16) 0.07
Metabolic syndrome 286 (49) 104 (53) 182 (46) 0.12
Framingham risk score 7 (5–9) 7.1  3.3 7 (5–9) 7.5  3.4 7 (5–9) 6.9  3.3 0.04
History of tobacco use 287 (48) 98 (50) 189 (47) 0.57
eGFR, ml/min/1.73 m2* 98 (76.2–123.4) 98.4 (78–121.1) 97.8 (75.3–124.7) 0.91
Total cholesterol, mg/dl 172 (149–202) 173 (150–202) 172 (149–202) 0.53
HDL-cholesterol, mg/dl 38.6 (34.0–47.0) 38.6 (33.0–48.0) 38.6 (34.0–45.0) 0.72
LDL-cholesterol, mg/dl 101.7 (80.4–129.0) 102.0 (81.2–129–8) 101 (79.2–128.2) 0.88
Triglycerides, mg/dl 125.0 (86.6–177.1) 138 (95.0–177.1) 121.5 (88.6–177.1) 0.04
Baseline C-reactive protein, mg/dl 7.0 (2.4–18.7) 6.8 (2.5–19.5) 7.0 (2.3–18.4) 0.88
Medications at discharge
Statins 521 (86) 177 (89) 344 (85) 0.19
Aspirin 591 (97) 193 (97) 398 (97) 0.58
Clopidogrel/ticlopidine 591 (97) 196 (98) 395 (97) 0.33
RAAS inhibitors 411 (67) 142 (71) 269 (66) 0.21
Beta-blockers 552 (91) 185 (93) 367 (90) 0.27
Diabetic medications (insulin or other) 94 (16) 39 (20) 55 (14) 0.052
Values are median (25th and 75th percentiles), n (%), or mean  SD. *eGFR was computed using the Modiﬁcation of Diet in Renal Disease formula (38).
CAD ¼ coronary artery disease; eGFR ¼ estimated glomerular ﬁltration rate; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; MI ¼ myocardial
infarction; RAAS ¼ renin-angiotensin-aldosterone system.
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1266(Fig. 1) and by multivariable Cox regression analysis
(hazard ratio: 2.45; 95% CI: 1.48 to 4.04; p ¼
0.006).
Factors associated with the high-risk group. Variables
from Tables 1 and 2 with p < 0.2 associated
with the presence of at least 2 of the 3 high-risk
plaque characteristics are shown in Table 4.
Multivariable analysis, performed including only theclinical variables, showed that only the Framingham
score was independently associated with the pres-
ence of high-risk plaque characteristics (OR: 1.05;
95% CI: 1.00 to 1.11; p ¼ 0.047), although with
poor discrimination in detecting patients belonging
to the high-risk group (optimal cutoff value for
the Framingham risk score 8; area under the curve
0.55). When the angiographic ﬁndings were
Table 2. Quantitative Coronary Angiographic Findings in the Study Population and the High-Risk and Low-Risk Groups
Study Population
(N [ 609)
High-Risk Group
(n [ 200)
Low-Risk Group
(n [ 409) p Value
Number of vessels with culprit lesions 1 (1–2)
1.29  0.46
1 (1–2)
1.35  0.48
1 (1–2)
1.27  0.44
0.035
Number of epicardial vessels with nonculprit lesions 1 (1–2)
1.41  0.98
2 (1–2)
1.56  0.97
1 (1–2)
1.34  0.98
0.007
Maximum diameter stenosis, % 46 (38–58) 47 (39–57) 45 (37–59) 0.72
Total length of nonculprit lesions, cm 20.0 (8.4–37.0) 26.3 (13.6–44.7) 16.8 (6.7–33.0) <0.0001
Number of nonculprit lesions 2 (1–4) 3 (2–4) 2 (1–3) <0.0001
Presence of lesions in side branches 199 (33) 87 (44) 112 (27) <0.0001
Thrombotic lesions 0 (0–0)
0.01  0.09
0 (0–0)
0.00  0.00
0 (0–0)
0.01  0.11
0.12
Calciﬁed lesions 0 (0–0)
0.04  0.23
0 (0–0)
0.05  0.24
0 (0–0)
0.04  0.23
0.51
Values are median (25th and 75th percentiles), mean  SD, or n (%).
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1267included in the multivariable model, only the
number of nonculprit lesions (OR: 1.17; 95% CI:
1.07 to 1.29; p ¼ 0.001) and the number of side
branches affected (OR: 1.54; 95% CI: 1.04 to 2.28;
p ¼ 0.031) were independently related to the high-
risk group. The combination of demographic and
angiographic factors slightly improved the discrim-
ination of the model (optimal cutoff value for the
number of nonculprit lesions was 1 and for the
number of side branches affected was 1; area under
the curve 0.64) (Fig. 2).
D I SCUSS ION
The present analysis examined the association be-
tween clinical and angiographic characteristics and
high-risk coronary plaque phenotype in patients
treated for an acute coronary event. We found that:
1) patients with $2 IVUS-VH–derived plaque
features related to future adverse events had a higher
Framingham risk score and more extensive coronary
artery disease on coronary angiography; and 2) the
information provided by the patient’s medical his-
tory and coronary angiography does not sufﬁciently
discriminate among patients with versus without
high-risk plaques to obviate the need for more
intensive imaging.
Several prior studies have used IVUS-VH to
explore the relationship between clinical factors and
plaque composition (10,11,13). Philipp et al. (10)
found that women were more likely to have calci-
ﬁed coronary arteries and a lower plaque burden and
that patients with diabetes had an increased necrotic
core component. Missel et al. (13) reported that
lipid proﬁle and smoking history were associated
with the ratio of necrotic core to dense calcium. Inanother study, Marso et al. (11) showed that pa-
tients with a high cardiovascular risk proﬁle, esti-
mated by the Framingham risk model, were more
likely to have TCFA phenotype stenoses compared
with low-risk patients. A signiﬁcant limitation of all
of these studies, however, is that IVUS-VH exam-
ination was restricted to the culprit vessel, and thus,
the measured plaque components may not reﬂect
the composition of the atheroma in the entire cor-
onary tree.
The present study, as the ﬁrst to use 3-vessel
IVUS-VH imaging, overcomes this limitation.
Also, in contrast to previous reports, we focused on
identiﬁcation of the patients with lesions containing
$2 high-risk plaque features because the PROS-
PECT study found a relationship between the
number of high-risk plaque characteristics and the
subsequent nonculprit lesion–related event rate (6).
Similarly to Marso et al. (9), we found an increased
Framingham risk score in the high-risk group but
no other signiﬁcant differences in the baseline de-
mographic characteristics between patients with and
without high-risk plaques. This ﬁnding may be at
least partially attributed to the fact that the
PROSPECT trial enrolled a uniform patient pop-
ulation, all of whom had ACS. Prior studies have
demonstrated differences in plaque composition in
patients admitted with different clinical syndromes,
with the likelihood of TCFAs being increased
in those with ACS compared with stable angina
(3,4). In our study, clinical variables had poor
discrimination in identifying high-risk plaque
characteristics.
This ﬁnding can be attributed to the multifac-
torial etiology of coronary atherosclerosis, which is
modulated not only by clinical factors but also by
Table 3. IVUS and IVUS-VH Findings of Nonculprit Lesions in the Study Population and the High-Risk and Low-Risk Groups
Study Population
(N [ 609)
High-Risk
Group (n [ 200)
Low-Risk Group
(n [ 409) p Value
Gray-scale IVUS
Entire lesion
Total lesion length, mm 73.3 (45.8–103.8) 96.5 (72.5–124.8) 61.9 (38.8–90.3) <0.0001
Average EEM CSA, mm2 16.12 (13.91–18.62) 15.35 (13.59–17.25) 16.66 (14.21–19.16) <0.0001
Average lumen CSA, mm2 8.11 (6.87–9.49) 7.33 (6.33–8.62) 8.55 (7.20–9.86) <0.0001
Average plaque area, mm2 7.88 (6.80–9.34) 7.81 (6.90–9.19) 7.91 (6.75–9.54) 0.63
Lesion with the smallest
MLA per patient
Lesion length, mm 11.38 (5.77–21.54) 13.93 (6.60–25.75) 10.10 (5.32–18.56) <0.0001
EEM cross-sectional area, mm2 14.16 (10.60–18.23) 13.51 (10.06–17.45) 14.55 (10.98–18.83) <0.0001
MLA, mm2 5.88 (4.32–8.08) 5.14 (3.77–7.17) 6.29 (4.76–8.57) <0.0001
Plaque area, mm2 7.82 (5.82–10.60) 7.76 (5.85–10.59) 7.84 (5.81–10.60) 0.86
Plaque burden, % 55.4 (49.1–62.8) 58.7 (51.6–66.5) 53.7 (48.2–60.6) <0.0001
Remodeling index 0.94 (0.85–1.00) 0.93 (0.84–1.00) 0.94 (0.85–1.00) 0.11
IVUS-VH
Entire lesion
Average necrotic
core area, mm2
0.50 (0.30–0.78) 0.68 (0.42–0.97) 0.45 (0.26–0.67) <0.0001
Average ﬁbrous
tissue area, mm2
2.54 (1.91–3.24) 2.63 (2.00–3.23) 2.52 (1.88–3.24) 0.43
Average ﬁbrofatty
tissue area, mm2
0.84 (0.54–1.27) 0.77 (0.47–1.05) 0.90 (0.57–1.38) 0.0007
Average dense
calcium area, mm2
0.21 (0.11–0.40) 0.28 (0.16–0.46) 0.19 (0.10–0.35) <0.0001
MLA site
Necrotic core area, mm2 0.48 (0.19–1.01) 0.65 (0.28–1.24) 0.39 (0.16–0.85) <0.0001
Fibrous tissue area, mm2 2.66 (1.65–4.13) 2.76 (1.65–4.24) 2.64 (1.66–4.03) 0.24
Fibrofatty tissue area, mm2 0.79 (0.33–1.52) 0.67 (0.26–1.33) 0.85 (0.37–1.64) <0.0001
Dense calcium area, mm2 0.15 (0.03–0.44) 0.22 (0.06–0.54) 0.12 (0.02–0.37) <0.0001
Lesion phenotype
Thin-cap ﬁbroatheroma 22.3 34.9 14.9 <0.0001
Thick-cap ﬁbroatheroma 37.9 35.9 39.0 0.090
Pathological intimal
thickening
36.2 26.3 42.0 <0.0001
Fibrotic 2.5 1.9 2.9 0.10
Fibrocalciﬁc 1.1 1.0 1.2 0.67
Values are median (25th and 75th percentiles) or %.
CSA ¼ cross-sectional area; EEM ¼ external elastic membrane; IVUS ¼ intravascular ultrasound; MLA ¼ minimum lumen area; VH ¼ virtual histology.
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1268vessel wall inﬂammation, genotype, and local he-
modynamic factors. In the PROSPECT trial, the
baseline level of C-reactive protein (CRP), a
biomarker associated with vascular inﬂammation,
was not related to high-risk plaque characteristics.
This may be due to the fact that baseline CRP level
was increased by the acute coronary event, which
masked the effect of chronic vascular inﬂammation
(14–16). CRP measurements at follow-up were not
considered in our analysis.Characteristics of several other biomarkers that
have been associated with future adverse cardiac
events (i.e., myeloperoxidase, A2 phospholipase,
blood monocyte subset counts, pregnancy-associated
plasmaprotein A, and patients’ hematology pro-
ﬁles) and are likely to affect plaque’s phenotype
were not available in this study (7,17–19).
Currently, the European Collaborative Project
on Inﬂammation and Vascular Wall Remodeling
in Atherosclerosis–Intravascular Ultrasound trial
Figure 1. Prognosis in the High-Risk and Low-Risk Groups
Kaplan-Meier curves showing the nonculprit lesion-related major adverse cardiac event
(MACE) rate in the high-risk (n ¼ 200) and low-risk (n ¼ 409) groups. CI ¼ conﬁdence
interval; HR ¼ hazard ratio.
Table 4. Variables Associated With the High-Risk Group
Odds Ratio (95% CI) p Value
Clinical characteristics
Increasing systolic blood pressure, per 10 mm Hg 1.07 (0.99–1.15) 0.111
History of diabetes 1.48 (0.96–2.28) 0.07
Increasing Framingham risk score, per unit 1.05 (1.00–1.11) 0.048
History of hypertension 1.31 (0.93–1.85) 0.17
Presence of metabolic syndrome 1.32 (0.93–1.86) 0.12
Angiographic characteristics
Number of culprit vessels 1.46 (1.01–2.10) 0.042
Number of epicardial vessels with lesions 1.27 (1.06–1.51) 0.008
Number of nonculprit lesions 1.23 (1.12–1.34) <0.0001
Number of side branches with nonculprit lesions 2.04 (1.43–2.91) <0.0001
Total length of nonculprit lesions, per mm 1.02 (1.01–1.03) <0.0001
CI ¼ conﬁdence interval.
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1269(NCT01789411) is underway and aims to examine
the prognostic value of circulating chemokines and
their association with plaque’s phenotype, as
determined by IVUS-VH. Genotype has been
shown to affect atherosclerotic evolution, and
several reports have provided evidence that vessel
geometry (especially in bifurcations) affects local
endothelial shear stress through which mechano-
receptors inﬂuence plaque metabolism and pro-
gression (20–22).
Although the number of nonculprit lesions and
the number of side branches affected was indepen-
dently associated with the presence of high-risk
plaques, the inclusion of QCA-derived measures
had a minor impact on the predictive accuracy of the
multivariable model. These ﬁndings are in agree-
ment with a recent report that demonstrated a weak
correlation between the presence of lipid-rich pla-
ques (as detected by near-infrared spectroscopy) and
the SYNTAX (Synergy Between PCI With Taxus
and Cardiac Surgery) score (23). Angiography is
limited to the visualization of luminal anatomy and
does not provide meaningful information about the
composition of plaque.
Over the last several years, numerous clinically
derived risk scores have been developed to predict
outcomes in patients presenting with ACS (24–28).
These risk stratiﬁcation models are moderately ca-
pable of predicting mortality, but they have a low
discrimination in predicting future events (29). To
address this limitation, several new scores have been
proposed that combine clinical with biochemical or
angiographic variables. However, these modiﬁcations
have only slightly increased the accuracy of the new
models in predicting future events (30,31). The
PROSPECT, VIVA (VH-IVUS in Vulnerable
Atherosclerosis), and PREDICTION (Prediction of
Progression of Coronary Artery Disease and Clinical
Outcome Using Vascular Proﬁling of Shear Stress
and Wall Morphology) studies provided robust evi-
dence that atheroma burden and the TCFA pheno-
type are strongly associated with plaque vulnerability
(6,32,33). The present analysis for the ﬁrst time
showed that the coronary plaque phenotype, which is
independently associated with nonculprit lesion–
related MACE, cannot be predicted by the clinical
and angiographic ﬁndings, emphasizing the potential
value of more comprehensive plaque characterization
(with either intravascular or noninvasive imaging)
for more accurate risk stratiﬁcation. Advances in in-
travascular imaging are expected to allow complete
plaque characterization, and thus, an assessment of
the whole coronary tree with upcoming invasive im-
aging techniques is anticipated to allow more accuraterisk stratiﬁcation (34). However, the additional time
and cost, risk of complications, increased time
required to process the obtained data, and lack of
evidence about how we should treat high-risk patients
make unrealistic the regular application of 3-vessel
invasive imaging in clinical settings.
Noninvasive imaging carries a great potential
because it overcomes the abovementioned limita-
tions of intravascular imaging modalities. Computed
tomographic coronary angiography appears able to
provide information about the type of plaque, and
there are robust data demonstrating its prognostic
value in asymptomatic or symptomatic stable patients
(34,35). Nevertheless, further research is required to
Figure 2. Efﬁciency of Baseline Demographics and Angiographic Variables in
Predicting Plaque’s Phenotype
Receiver-operating characteristic curve plot demonstrating the efﬁciency of the clinical
variables (area under the curve [AUC] 0.55) and clinical plus angiographic variables (AUC
0.64) in identifying patients with a high-risk plaque phenotype. Abbreviation as in Figure 1.
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with acute myocardial infarction.
Study limitations. The criteria used to categorize
patients into the high-risk and low-risk groups in
the present study were based on the ﬁndings from
the PROSPECT trial, in which lesions exhibitingFigure 3. Event Rate at a Lesion Level
MACE rate at 3 years for lesions with no or only 1 high-risk char-
acteristic and for those with 2 or 3 high-risk features. Abbreviation
as in Figure 1.$2 high-risk plaque characteristics had a 9-fold
incidence to progress and cause future MACE
within 3 years compared with lesions having #1
high-risk plaque characteristics (Fig. 3). Although
recently the VIVA study reported that the same
IVUS-derived characteristics were associated with
future adverse cardiac events (i.e., the presence of a
TCFA, plaque burden$70%, and MLA #4 mm2),
the criteria of our study requires prospective vali-
dation in future studies. In addition, most of the
MACE reported in the PROSPECT trial were due
to repeat hospitalizations for stable or unstable
angina symptoms, and thus, it is unclear whether
the high-risk plaque characteristics used in this
analysis to classify patients are able to predict
nonculprit-related cardiac death or myocardial
infarction. Fractional ﬂow reverse evaluation was
not part of the protocol in the PROSPECT study.
Therefore, it is likely that hemodynamically signif-
icant lesions were left untreated during the index
procedure and caused future events that may have
affected the reported results.
The strict inclusion criteria used in the PROS-
PECT trial (e.g., patients with severe renal failure or
ejection fraction <30% were excluded from the
analysis) may have affected the reported association
between baseline characteristics and the phenotype of
the plaque. With only 609 patients in the present
study, we lacked the power to identify modest re-
lationships between all risk factors and high-risk
plaque phenotype. Finally, IVUS-VH imaging has
limitations, including the only moderate radial reso-
lution and limited capability to detect the composi-
tion of the atheroma behind calcium deposits, which
may have affected the results of this analysis (36,37).
CONCLUS IONS
The present study demonstrated that clinical vari-
ables have poor discrimination in detecting which
patients presenting with ACS have high-risk non-
culprit plaques. The addition of angiographic ﬁnd-
ings only slightly improved the accuracy of the
developed model but not to the extent the need
was obviated for more comprehensive plaque char-
acterization. Future studies of invasive and nonin-
vasive plaque evaluation may be useful in identifying
patients who remain high risk after being success-
fully treated for ACS.Reprint requests and correspondence: Dr. Patrick W.
Serruys, ThoraxCenter, Erasmus Medical Center,
‘s-Gravendijkwal 230, 3015 CE Rotterdam, the
Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl.
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